VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

Jan 23, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-01-19

Reporting Person: Kelly Lisa (SVP, Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-01-19	Common Stock	S	10166	$37.00	Disposed	26542	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1667	Indirect

Footnotes

F1: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.84 to $37.15).

F3: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.